Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02007577 · ClinicalTrials.gov registry record · NA
Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?
A NA study of Pre Diabetes and Insulin Resistant, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02007577 is a NA study of Pre Diabetes and Insulin Resistant that has completed, run by Stanford University. The registered enrollment target is 41 participants, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02007577, a NA study of Pre Diabetes and Insulin Resistant, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The possibility that obesity-associated inflammatory changes may play a role in the pathogenesis of type 2 diabetes (2DM) has led to increased interest in the possibility that salicylates might represent a useful treatment to improve glucose tolerance. Several studies, performed in patients with 2DM, as well as in nondiabetic, obese individuals, have demonstrated that salicylates have beneficial effects on glucose and insulin metabolism, but have not led to a coherent view as to the mechanism(s) involved. In this research proposal we will use specific methods to quantify insulin mediated glucose uptake (IMGU), glucose-stimulated insulin secretion rate (GS-ISR), and insulin clearance (I-Cl) in overweight/obese, nondiabetic, insulin resistant individuals. We will use the insulin suppression test (IST) to quantify IMGU in nondiabetic, overweight/obese volunteers to identify those individuals who are sufficiently insulin resistant to be enrolled in this study. We will then use the graded glucose infusion technique in these insulin resistant subjects to generate specific measures of both GS-IS and I-Cl. Following these baseline measurements, salsalate or placebo will be administered for one month to the participants, after which time the IST and the graded glucose infusion will be repeated to quantify and compare the changes in IMGU, GS-ISR, and I-Cl that have resulted from salsalate versus placebo. These results will provide for the first time quantitative data of the effect of salicylates on IMGU, GS-ISR, and I-Cl in overweight/obese, insulin resistant, nondiabetic individuals.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG salsalate
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02007577
The ClinicalTrials.gov registry entry for NCT02007577 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (94% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pre Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02007577 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02007577 about?
NCT02007577 is a clinical study titled "Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?". The possibility that obesity-associated inflammatory changes may play a role in the pathogenesis of type 2 diabetes (2DM) has led to increased interest in the possibility that salicylates might represent a useful treatment to improve glucose tolerance. Several studies, performed in patients with 2DM...
What is the current status of trial NCT02007577?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2010-07. Estimated completion is 2013-11.
What conditions does trial NCT02007577 study?
This clinical trial studies the following conditions: Pre Diabetes, Insulin Resistant.
What interventions are being tested in trial NCT02007577?
The interventions under investigation include: Placebo (DRUG), salsalate (DRUG).
Who is sponsoring clinical trial NCT02007577?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02007577 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals
RECRUITING · NA
-
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
RECRUITING · NA
-
Stand Up for Your Health with a Sit-stand Desk
RECRUITING · NA
-
Sisters of Heart (Hermanas de Corazón): A Community Health Worker Initiative for Improving Heart Health in Migrant Farmworker Women
RECRUITING · NA
-
Full Plate Living Nutrition Education Program
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.